Beyond market trends, investors looking for superior returns explore the world of stock picking. The right selections can be a powerful driver for wealth accumulation.
The closing price of Cogent Biosciences Inc (NASDAQ: COGT) was $4.98 for the day, up 2.05% from the previous closing price of $4.88. In other words, the price has increased by $2.05 from its previous closing price. On the day, 0.71 million shares were traded.
Ratios:
Our analysis of COGT’s different ratios will help us gain a deeper understanding of the company. For the most recent quarter (mrq), Quick Ratio is recorded 5.13 and its Current Ratio is at 5.13. In the meantime, Its Debt-to-Equity ratio is 0.08 whereas as Long-Term Debt/Eq ratio is at 0.07.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, Scotiabank on March 07, 2025, initiated with a Sector Outperform rating and assigned the stock a target price of $17.
Robert W. Baird Downgraded its Outperform to Neutral on February 26, 2024, whereas the target price for the stock was revised from $14 to $8.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 14 ’25 when Pinnow Cole bought 43,750 shares for $7.60 per share. The transaction valued at 332,412 led to the insider holds 45,848 shares of the business.
Stock Price History:
Over the past 52 weeks, COGT has reached a high of $12.61, while it has fallen to a 52-week low of $3.72. The 50-Day Moving Average of the stock is -10.08%, while the 200-Day Moving Average is calculated to be -41.34%.
Shares Statistics:
A total of 113.86M shares are outstanding, with a floating share count of 94.03M. Insiders hold about 17.41% of the company’s shares, while institutions hold 100.05% stake in the company.
Earnings Estimates
The dynamic stock of Cogent Biosciences Inc (COGT) is currently being evaluated by a team of 9.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is -$0.53, with high estimates of -$0.31 and low estimates of -$0.67.
Analysts are recommending an EPS of between -$1.49 and -$2.63 for the fiscal current year, implying an average EPS of -$2.18. EPS for the following year is -$1.89, with 8.0 analysts recommending between -$1.13 and -$2.9.
